866-997-4948(US-Canada Toll Free)

Acromegaly - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Metabolic Disorders

No. of Pages : 92 Pages

Acromegaly - Pipeline Review, H1 2014

Summary

Global Markets Directs, Acromegaly - Pipeline Review, H1 2014, provides an overview of the Acromegalys therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acromegaly, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acromegaly and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acromegaly
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acromegaly and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acromegaly products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acromegaly pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acromegaly
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Acromegaly Overview 8
Therapeutics Development 9
Pipeline Products for Acromegaly Overview 9
Pipeline Products for Acromegaly Comparative Analysis 10
Acromegaly Therapeutics under Development by Companies 11
Acromegaly Therapeutics under Investigation by Universities/Institutes 13
Acromegaly Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Acromegaly Products under Development by Companies 18
Acromegaly Products under Investigation by Universities/Institutes 19
Acromegaly Companies Involved in Therapeutics Development 20
Ipsen S.A. 20
Novartis AG 21
Antisense Therapeutics Limited 22
Paladin Labs Inc. 23
Camurus AB 24
GP Pharm, S.A. 25
Aegis Therapeutics, LLC 26
Peptron, Inc. 27
Q Chip Ltd. 28
Crinetics Pharmaceuticals, Inc. 29
Chiasma, Inc. 30
Foresee Pharmaceuticals, LLC 31
DexTech Medical AB 32
Acromegaly Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Target 34
Assessment by Mechanism of Action 37
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
pasireotide LAR - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
octreotide acetate - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ATL-1103 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
DG-3173 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
octreotide acetate - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
octreotide acetate - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
octreotide acetate LAR - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Somadex - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
pasireotide LAR - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
SXN-101959 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Recombinant Proteins to Antagonize Growth Hormone Receptor for Acromegaly - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
FP-002 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
octreotide SR - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
octreotide - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
G-02113 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
SXN-101742 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Small Molecules To Agonize Somatostatin For Acromegaly - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
octreotide acetate SR - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Acromegaly Recent Pipeline Updates 69
Acromegaly Dormant Projects 78
Acromegaly Discontinued Products 79
Acromegaly Product Development Milestones 80
Featured News & Press Releases 80
Jan 07, 2014: Antisense Therapeutics Selected to Present at Biotech Showcase 2014 80
Dec 23, 2013: Positive Results Achieved from Interim Analysis of ATL1103 Phase II Trial 81
Nov 26, 2013: ATL1103 Phase II Trial Update 83
Oct 17, 2013: ATL1103 Phase II Trial Update - Interim Analysis 83
Aug 02, 2013: Antisense Therapeutics Provides ATL1103 Phase II Trial Update 85
Jun 29, 2013: Somatuline Subcutaneous Injection Approved as Treatment for Acromegaly and Pituitary Gigantism in Japan 86
Jun 17, 2013: Ipsen Announces Clinically Relevant Results In Phase III PRIMARYS Study With Somatuline Autogel In Acromegaly Patients 87
Jun 14, 2013: Antisense Therapeutics Reports Positive New Animal Data On ATL1103 For Treatment Of Acromegaly 88
Apr 10, 2013: Antisense Therapeutics Commences Dosing Of Patients For Phase II Clinical Trial Of ATL1103 In Acromegaly 89
Apr 03, 2013: Aspireo Pharma Reports Somatoprim Phase IIa Proof Of Concept Results In Acromegaly 89
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 92
Disclaimer 92

List of Table

List of Tables
Number of Products under Development for Acromegaly, H1 2014 9
Number of Products under Development for Acromegaly Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Comparative Analysis by Unknown Stage Development, H1 2014 17
Products under Development by Companies, H1 2014 18
Products under Investigation by Universities/Institutes, H1 2014 19
Acromegaly Pipeline by Ipsen S.A., H1 2014 20
Acromegaly Pipeline by Novartis AG, H1 2014 21
Acromegaly Pipeline by Antisense Therapeutics Limited, H1 2014 22
Acromegaly Pipeline by Paladin Labs Inc., H1 2014 23
Acromegaly Pipeline by Camurus AB, H1 2014 24
Acromegaly Pipeline by GP Pharm, S.A., H1 2014 25
Acromegaly Pipeline by Aegis Therapeutics, LLC, H1 2014 26
Acromegaly Pipeline by Peptron, Inc., H1 2014 27
Acromegaly Pipeline by Q Chip Ltd., H1 2014 28
Acromegaly Pipeline by Crinetics Pharmaceuticals, Inc., H1 2014 29
Acromegaly Pipeline by Chiasma, Inc., H1 2014 30
Acromegaly Pipeline by Foresee Pharmaceuticals, LLC, H1 2014 31
Acromegaly Pipeline by DexTech Medical AB, H1 2014 32
Assessment by Monotherapy Products, H1 2014 33
Number of Products by Stage and Target, H1 2014 36
Number of Products by Stage and Mechanism of Action, H1 2014 39
Number of Products by Stage and Route of Administration, H1 2014 41
Number of Products by Stage and Molecule Type, H1 2014 43
Acromegaly Therapeutics Recent Pipeline Updates, H1 2014 69
Acromegaly Dormant Projects, H1 2014 78
Acromegaly Discontinued Products, H1 2014 79

List of Chart

List of Figures
Number of Products under Development for Acromegaly, H1 2014 9
Number of Products under Development for Acromegaly Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Early Stage Products, H1 2014 16
Assessment by Monotherapy Products, H1 2014 33
Number of Products by Top 10 Target, H1 2014 34
Number of Products by Stage and Top 10 Target, H1 2014 35
Number of Products by Top 10 Mechanism of Action, H1 2014 37
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 38
Number of Products by Top 10 Route of Administration, H1 2014 40
Number of Products by Stage and Top 10 Route of Administration, H1 2014 41
Number of Products by Top 10 Molecule Type, H1 2014 42
Number of Products by Stage and Top 10 Molecule Type, H1 2014 43

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *